

23 May 2014 WG-III-2014

Revised Draft Agenda Biocides Working Group Meeting III - 2014

2-6 June 2014 ECHA Conference Centre (Annankatu 18, Helsinki) Meeting room Margot Wallström

> Coffee break 10:30-11:00 Lunch break 12:30-13:30 Coffee break 15:00-15:30

Monday 02 June	09:30-12:30 13:30-18:00	APCP WG	
Tuesday 03 June	09:00-12:30 13:30-18:00	EFF WG	
Wednesday 04 June	09:00-12:30 13:30-18:00	TOX WG	EFF Guidance WS
Thursday 05 June	09:00-12:30 13:00-17:00	TOX WG ENV WG	EFF Guidance WS
Friday 06 June	09:00-12:30 13:30-16:00	ENV WG	

Analytical methods and physical-chemical properties Working Group

Chair: Bernhard Krebs

Item 1 – Welcome and apologies

Item 2 – Agreement of the agenda

For agreement

Item 3 – Declarations of potential conflicts of interest in relation to the agenda

Item 4 – Agreement of the draft minutes from WG-II-2014

For agreement

Item 5 – Administrative issues

5.1 Housekeeping issues

For information

Item 6 – Establishment of a reference specification

6.1 Reference source for biocidal active substances under the Biocidal Products Regulation (BPR) (EU) No 528/2012 Meeting document: WGIII2014_APCP_6-1_Specification, Reference specification, Source and Reference source – Terminology used for processes under the BPR Previous discussion(s): WGII2014

For discussion/agreement

6.2 Approved active substances without reference specification Meeting document: *WGIII2014_APCP_6-2_Approved active substances with unclear reference specification / reference source* Previous discussion(s): none

For discussion/agreement

Item 7 – Technical equivalence assessments

7.1 Tebuconazole – DK

Meeting document: *WGIII2014_APCP_7-1_TE Tebuconazole* Previous discussion(s): none

For discussion/agreement

Item 8 – Dry matter calculation

8.1 Method to be used for the calculation of the dry matter Meeting document: *WGIII2014_APCP_8-1_Dry matter calculation* Previous discussion(s): WGII2014

For discussion/agreement

Item 9 - Redefinition of substances with regard to SID

9.1 PHMB

Meeting document: *WGIII2014_APCP_9-1_Chemical similarity of PHMB* Previous discussion(s): e-consultation

For discussion/agreement

9.2 Pyrethrin and Chrysanthemum cinerariaefolium extract Meeting document: *WGIII2014_APCP_9-2_Chemical similarity between Chrysanthemum cinerariaefolium, ext. and Pyrethrins and Pyrethroids* Previous discussion(s): none

For discussion/agreement

Item 10 – Discussion of active substances

10.1 Ampholyt 20 (eCA IE)

Meeting document: *WGIII2014_APCP_10-1_Discussion table Ampholyt 20* Previous discussion(s): none

For discussion/agreement

10.2 MBM (eCA AT)

Meeting document: *WGIII2014_APCP_10-2_Discussion table MBM* Previous discussion(s): none

For discussion/agreement

10.3 Propiconazole (eCA FI) Meeting document: *WGIII2014_APCP_10-3_Discussion table Propiconazole* Previous discussion(s): none

For discussion/agreement

Item 11 – AOB

Efficacy Working Group

Chair: Ann Thuvander

Item 1 – Welcome and apologies

Item 2 – Agreement of the agenda

For agreement

Item 3 – Declarations of potential conflicts of interest in relation to the agenda

Item 4 – Agreement of the draft minutes from WG-II-2014

- WGII2014_EFF_draft_minutes.docx
- WGII2014_EFF_5-1_draft_minutes.docx
- WGII2014_EFF_5-2_draft_minutes.docx
- WGII2014_EFF_5-3_draft_minutes_updated.docx

For agreement

Item 5 – Administrative issues

5.1 Housekeeping issues

For information

Item 6 – Discussion of active substances (in case of open issues)

6.1 Ampholyt 20 (eCA IE)

PT 2, 3, 4 Meeting document: *WGIII2014_EFF_6-1* Previous discussion(s): None

6.2 MBM (eCA AT) PT 6, 13

Meeting document: *WGIII2014_EFF_6-2* Previous discussion(s): None

6.3 Propiconazole (eCA FI) PT 7 Meeting document: *WGIII2014_EFF_6-3* Previous discussion(s): None

For agreement

For agreement

For agreement

- 7.1 Efficacy of piperonyl butoxide (PBO) for PT18 WGIII2014_EFF_7-1
- **7.2 Work plan for Efficacy guidance** *WGIII2014_EFF_7-2*
- 7.3 Update of Pt 14 guidance WGIII2014_EFF_7-3

For information

For information

For discussion

Item 8 – AOB

8.1 Lessons learned Discussion on the experience gained

For information

Efficacy guidance Workshop

Item 1 – Welcome and apologies

Item 2 – Discussion on Efficacy guidance under preparation (PT 1, 3, 4)

Human Health Working Group

Chair: Antero Airaksinen

Item 1 – Welcome and apologies

Item 2 – Agreement of the agenda

For agreement

Item 3 – Declarations of potential conflicts of interest in relation to the agenda

Item 4 – Agreement of the draft minutes from WG-II-2014

Meeting documents:

- WGII2014_TOX_draft_minutes_updated.docx
- WGII2014_TOX_5-1 CO2_PT15_draft_minutes.docx
- WGII2014_TOX_5-2_OIT PT6_13_draft_minutes_updated.docx
- WGII2014_TOX_5-3 _Copper pyrithione PT21_draft_minutes_updated.docx
- WGII2014_TOX_5-4_Dinotefuran PT18_draft_minutes_updated.doc
- WGII2014_TOX_5-5_CMIT-MIT_PT2_4_6_11_12_13_draft_minutes_updated.docx
 WGII2014_TOX_5-5_CMIT-
 - MIT_PT2_4_6_11_12_13_draft_minutes_CONFIDENTIAL.docx

For agreement

Item 5 – Administrative issues

5.1 Housekeeping issues

For information

Item 6 – Discussion of active substances

6.1 MBM (eCA AT)

PT 6, 13 Meeting document: *WGIII2014_TOX_6-1* Previous discussion(s): None *Provisionally scheduled for Wednesday 4 June*

For agreement

6.2 Propiconazole (eCA FI)

PT 7 Meeting document: *WGIII2014_TOX_6-2* Previous discussion(s): None *Provisionally scheduled for Wednesday 4 June*

6.3 Ampholyt 20 (eCA IE)

PT 2, 3, 4 Meeting document: *WGIII2014_TOX_6-3* Previous discussion(s): None *Provisionally scheduled for Wednesday 4 June*

6.4 Cholecalciferol (eCA SE)

PT 14 Early WG discussion during eCA evaluation Meeting document: *WGIII2014_TOX_6-4* Previous discussion(s): None *Provisionally scheduled for Thursday 5 June*

6.5 PHMB (eCA FR)

Early WG discussion on criteria used for substance identity (FR to inform) The discussion of this agenda item depends on the outcome of the APCP WG discussion.

Provisionally scheduled for Thursday 5 June

For information

Item 7 – Technical and guidance related issues

7.1 Guidance development

SECR to inform

For information

7.2 Guidance for Human Health Risk Assessment – Volume III, Part B Discussion to start collecting input for the future revision

For discussion

Item 8 – AOB

8.1 Lessons learned

Discussion on the experience gained

For information

For agreement

For agreement

For agreement

Environment Working Group

Chair: Heike Schimmelpfennig

Item 1 – Welcome and apologies

Item 2 – Agreement of the agenda

For agreement

Item 3 – Declarations of potential conflicts of interest in relation to the agenda

Item 4 – Agreement of the draft minutes from WG-II-2014

Meeting documents:

- WGII2014_ ENV_6-1_Draft minutes updated
- WGII2014_ ENV_6-2_Draft minutes updated
- WGII2014_ENV_6-3_Draft minutes updated
- WGII2014_ENV_6-4_Draft minutes updated
- WGII2014_ENV_Draft minutes updated

For agreement

Item 5 – Administrative issues

5.1 Housekeeping issues

For information

Item 6 – Discussion of active substances

6.1 MBM (eCA AT)

PT 6, 13 Meeting document: *WGIII2014_ENV_6-1* Previous discussion(s): None *Provisionally scheduled for Thursday 5 June*

For agreement

6.2 PHMB (eCA FR)

Early WG discussion on criteria used for substance identity (FR to inform) The discussion of this agenda item depends on the outcome of the APCP WG discussion.

Provisionally scheduled for Thursday 5 June

For information

9

6.3 Propiconazole (eCA FI)

PT 7 Meeting document: *WGIII2014_ENV_6-3* Previous discussion(s): None *Provisionally scheduled for Thursday 5 June*

For agreement

Cholecalciferol (eCA SE) PT 14 Meeting document: *WGIII2014_ENV_6-4* Early WG discussion during eCA evaluation Previous discussion(s): None *Provisionally scheduled for Friday 6 June*

6.5 Ampholyt 20 (eCA IE)

6.4

PT 2, 3, 4 Meeting document: *WGIII2014_ENV_6-5* Previous discussion(s): None *Provisionally scheduled for 5-6 June*

For agreement

For agreement

Item 7 – Ad Hoc Environmental Exposure WG and technical/guidance related issues

7.1 Introduction of the Ad Hoc Environmental Exposure WG (ECHA) SECR to inform

For information

7.2 Update on guidance development (ECHA) Meeting document: *WGIII2014_ENV_7-2* SECR to inform

For information (one point for agreement)

7.3 Direct emissions to surface waters in PT 6, 7, 8, 9 and 10 (DE)
Meeting document: To be provided by DE
Previous discussion: TM II 2013

For agreement

7.4 Use scenarios for PT09 roof membranes (DE) Meeting document: To be provided by DE Previous discussion: TM IV 2013

For agreement

Item 8 – AOB

8.1 Lessons learned

SECR/WG members to reflect on the experience gained

For information